Literature DB >> 24421558

nab-Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer.

Courtney E Porter1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 24421558      PMCID： PMC3887595          DOI： 10.1310/hpj4901-18

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  15 in total

1.  nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.

Authors:  Mikhail Y Biakhov; Galina V Kononova; Jose Iglesias; Neil Desai; Paul Bhar; Anita N Schmid; Sibylle Loibl
Journal:  Expert Opin Drug Saf       Date:  2010-07       Impact factor: 4.250

2.  Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

Authors:  Olga Geling; Hans-Georg Eichler
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 3.  Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Authors:  P J Hesketh; M G Kris; S M Grunberg; T Beck; J D Hainsworth; G Harker; M S Aapro; D Gandara; C M Lindley
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

4.  A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.

Authors:  Paul K Paik; Leonard P James; Gregory J Riely; Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; Camelia S Sima; Robert T Heelan; Mark G Kris; Erin Moore; Naiyer A Rizvi
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-03       Impact factor: 3.333

5.  Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.

Authors:  Dong-sheng Zhang; De-shen Wang; Zhi-qiang Wang; Feng-hua Wang; Hui-yan Luo; Miao-zhen Qiu; Feng Wang; Yu-hong Li; Rui-hua Xu
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-13       Impact factor: 3.333

6.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Authors:  Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544

7.  Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.

Authors:  Suzette Delaloge; Antonio Llombart; Mario Di Palma; Jean-Marc Tourani; Francois Turpin; Lan Ni; S T Forgue; Thierry Le Chevalier
Journal:  Am J Clin Oncol       Date:  2004-06       Impact factor: 2.339

Review 8.  Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Authors:  P E Kintzel; R T Dorr
Journal:  Cancer Treat Rev       Date:  1995-01       Impact factor: 12.111

Review 9.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

10.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245
View more
  2 in total

1.  Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.

Authors:  Emilie A G Molins; William J Jusko
Journal:  AAPS J       Date:  2018-06-27       Impact factor: 4.009

2.  Pancreatic cancer stromal biology and therapy.

Authors:  Dacheng Xie; Keping Xie
Journal:  Genes Dis       Date:  2015-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.